Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
about
Oligonucleotide Therapies: The Past and the PresentEstablishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide DrugsIntracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.Short-interference RNAs: becoming medicines.Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.Sequence-defined polymers for the delivery of oligonucleotides.Cellular uptake and intracellular trafficking of oligonucleotidesLipophilic 2'-O-Acetal Ester RNAs: Synthesis, Thermal Duplex Stability, Nuclease Resistance, Cellular Uptake, and siRNA Activity after Spontaneous Naked Delivery.Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials.Specific Increase of Protein Levels by Enhancing Translation Using Antisense Oligonucleotides Targeting Upstream Open Frames.Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling.Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNAIntra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotidesTargeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.Molecular Mechanisms of Antisense Oligonucleotides.Size, Shape, and Sequence-Dependent Immunogenicity of RNA Nanoparticles.Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice.Cytotoxicity of guanine-based degradation products contributes to the antiproliferative activity of guanine-rich oligonucleotides.Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain.Oligonucleotide modifications enhance probe stability for single cell transcriptome in vivo analysis (TIVA).Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides.Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi TherapeuticsCircular RNAs as Therapeutic Agents and TargetsCOPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
P2860
Q27002403-0EACCEAB-BFCE-4C84-9604-411151D59901Q28552808-A58F01A8-9C49-4A76-A708-5886454EBD88Q33786263-DAF9ECDF-17BC-45C5-8FF3-37966F405A45Q36228096-9D1F8169-E419-4D60-803A-D8FB28B04191Q36347546-8EBD2F4B-A19C-47EE-AF2E-3A6A280BEEFAQ36775577-A5023120-FEF9-413F-9C60-569E714E211BQ38291806-0972731C-D1D9-461A-85EF-5C11E847C913Q38298812-752B86B5-4DB5-4BEB-97CA-B3A314E2F7C2Q38424377-714990B0-3452-4F1E-8FF9-156F28814AEEQ38734379-B1A9986C-D5F9-42D1-B0E4-AD5124EAECD5Q39021948-3D69CC23-71D1-484A-B6AE-605675BA69D2Q39390082-517FC0EA-F551-4040-A804-D6142AD2F291Q40104372-7AC13125-1593-429C-ACE0-277BA03813CAQ40463360-12F1F2F7-C782-4BD8-B707-87A5DF729F7CQ41520047-70CB4DE7-7B8A-483E-9CE2-4D2237AC8E45Q41693957-53104E47-C3FB-4162-9DC8-7C56789C66F9Q41846059-A9789310-5FD7-4F01-834F-9C16888B2924Q42293314-71E615F1-A0CA-4D58-924E-C904CD580BBBQ47097375-B6F94A30-786A-4769-A139-4609BDB09A95Q47147153-97C72143-790A-4A12-BC4B-2785AC01D481Q47428247-AC167E63-EFC1-4A90-947B-9A36CC89EA43Q48208830-5A7C32A7-FD88-4801-92B0-C7C62EEEF423Q50101001-7ED06CC1-4396-4C6F-8B8F-91578B4F8E5DQ51743392-EA691574-7995-4D31-9CFC-7B1FF2BF9E6BQ55383414-14CC861A-82AE-43C4-949F-35D898F7B4CFQ57094579-B0FFF758-3BF6-4897-BE06-BC27AA9F7A25Q57817032-6ACCE4D1-E24F-4715-B0CA-852F5C76979DQ58708488-787A1F79-E896-4DAC-978E-EE0E5EEA4B88
P2860
Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@en
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@nl
type
label
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@en
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@nl
prefLabel
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@en
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@nl
P2093
P2860
P356
P1476
Cellular uptake and intracellu ...... oligonucleotide pharmacology.
@en
P2093
Brian Laing
Kyle Carver
R L Juliano
P2860
P304
P356
10.1089/NAT.2013.0463
P577
2014-01-02T00:00:00Z